Combining Radiopharmaceuticals with Targeted Radiation Improves Progression-Free Survival in Prostate Cancer Patients

Combining radiopharmaceuticals with targeted radiation improves progression-free survival in prostate cancer patients

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation, compared with radiation alone.

Radiopharmaceutical added to stereotactic radiation can delay prostate cancer progression

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation, compared with radiation alone.

Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer

The addition of 177Lu-PNT2002 did not significantly increase toxicity in patients with oligorecurrent prostate cancer who received SBRT.

ASTRO: Lu-177 PNT2002 added to SBRT delays prostate cancer progression

Two cycles of lutetium-177 PNT2002 before stereotactic body radiation therapy (SBRT) significantly improved progression-free survival.

Radiopharmaceutical Combined with Stereotactic Radiation Slows Progression

A groundbreaking clinical investigation has revealed a transformative approach in the management of recurrent prostate cancer presenting with limited metastatic spread, known as oligometastatic disease. This pioneering Phase II trial, dubbed LUNAR, explored the efficacy of combining a radiopharmaceutical agent with stereotactic body radiation therapy (SBRT) compared to SBRT alone. The results signify a significant […]

Radiopharmaceutical Added to Stereotactic Radiation Delays Prostate Cancer Progression in Patients with Limited Metastatic Disease

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation, compared with radiation alone.